<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940916-2-00061</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>National Toxicology Program; Availability of Technical Report on Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The HHS' National Toxicology Program announces the availability of the NTP Technical Report on the toxicology and carcinogenesis studies of 3,4-dihydrocoumarin, which is used as a flavoring agent in beverages, gelatins, puddings, candy, and other food items and as a fragrance in perfumes, creams, and cosmetics.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Toxicity and carcinogenicity studies were conducted by administering 3,4-dihydrocoumarin (99% pure) in corn oil by gavage to groups of 60 male and female F344/N rats at doses of 0, 150, 300, or 600 mg/kg body weight for 2 years. Groups of 70 male and female B6C3F mice received 3,4-dihydrocoumarin in corn oil by gavage at doses of 0, 200, 400, or 800 mg/kg body weight for 2 years.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Under the conditions of these 2-year gavage studies, there was some evidence of carcinogenic activity <FOOTCITE>1</FOOTCITE>  of 3,4-dihydrocoumarin in male F344/N rats based on increased incidence of renal tubule adenomas and focal hyperplasia. The transitional cell carcinomas in two 600 mg/kg males may also have been chemical related. There was no evidence of carcinogenic activity of 3,4-dihydrocoumarin in female F344/N rats receiving 150, 300, or 600 mg/kg. There was no evidence of carcinogenic activity of 3,4-dihydrocoumarin in male B6C3F1 mice receiving 200, 400, or 800 mg/kg. There was some evidence of carcinogenic activity in female B6C3F1 mice based on increased incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <FOOTNOTE> <FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> 1 <!-- PJG /ITAG -->  </FOOTNAME> <!-- PJG ITAG l=28 g=1 f=1 --> The NTP uses five categories of evidence of carcinogenic activity observed in each animal study: two categories for positive results (``clear evidence'' and ``some evidence''), one category for uncertain findings (``equivocal evidence''), one category for no observable effect (``no evidence''), and one category for studies that cannot be evaluated because of major flaws (``inadequate study'').  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FOOTNOTE>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 3,4-Dihydrocoumarin caused ulcers, hyperplasia, and inflammation of the forestomach, parathyroid gland hyperplasia, and increased severity of nephropathy in male rats.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Questions or comments about the Technical Report should be directed to Central Data Management at P.O. Box 12233, Research Triangle Park, NC 27709 or telephone (919) 541&hyph;3419.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Copies of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119&hyph;84&hyph;6) in F344/N Rats and B6C3F1 Mice (Gavage Studies) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (TR&hyph;423) are available without charge from Central Data Management, NIEHS, MD A0&hyph;01, P.O. Box 12233, Research Triangle Park, NC 27709; telephone (919) 541&hyph;3419.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: September 8, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Kenneth Olden,  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, National Toxicology Program.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;22815 Filed 9&hyph;15&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            